S1095 Obefazimod in Patients With Moderate-to-Severe Ulcerative Colitis: efficacy and Safety Analysis From the 96-Week Open-Label Maintenance Phase 2b Study

Authors
Category Primary study
ConferenceEmbase conference abstracts
Year 2026
This article has no abstract
Epistemonikos ID: a1d865541d07fcc06a6f0087c028367bf8d22918
First added on: Jun 15, 2026